Tumor-treating fields, a low-intensity, alternating electrical field delivered by transducers placed on the scalp, may have a selective anti-mitotic effect on glioblastoma, the most common primary brain tumor. This randomized controlled trial aimed to investigate whether tumor-treating fields improve progression-free survival and overall survival in patients with glioblastoma. Patients were randomized to receive either tumor-treating fields for more than 18 hours per day and temozolomide for 5 days per 28 cycle (n=466) or temozlomide alone at the same interval (n=229). Results showed a significantly longer progression-free survival when tumor-treating fields were administered, with a median progression-free survival of 6.7 months, as compared to 4.0 months in the temozolomide only group (HR 0.63, 95% CI 0.52 to 0.76, p<0.001). Median overall survival was also significantly greater in the group treated with tumor-treating fields (HR 0.63, 95% CI 0.53 to 0.76, p<0.001). Both treatment arms had similar rates of adverse effects. However, skin toxicity where the transducers were applied occurred in 52% of patients receiving tumor-treating fields. Investigators therefore concluded that the addition of tumor-treating fields in the treatment of glioblastoma improves both progression-free and overall survival with an acceptable adverse effect profile.
Early revascularization of the culprit coronary artery, by way of percutaneous coronary intervention (PCI), can significantly reduce the mortality associated with cardiogenic shock in the setting of acute myocardial infarction (MI). However, the majority of presenting patients have underlying multi-vessel coronary disease. Whether immediate PCI should be performed for clinically significant stenoses in non-culprit coronary arteries, however, is unclear. Immediate percutaneous revascularization of multi-vessel disease introduces additional risks such as induction of further ischemia, volume overload and kidney damage related to contrast material. This multicenter randomized controlled trial enrolled 706 patients with acute MI with multi-vessel disease and cardiogenic shock and assigned them to receive PCI of the lesion responsible for the myocardial infarction with possible staged revascularization of other lesions, or immediate multivessel PCI. Patients were followed up for a primary endpoint incorporating mortality and severe renal failure leading to renal-replacement therapy within 30 days. Researchers found that patients that received PCI for the culprit vessel only were significantly less likely to experience the study endpoint (RR 0.83, 95% CI 0.71 to 0.96, p=0.01). The risk of death alone was also significantly lower in the single vessel PCI group (RR 0.84, 95% CI 0.72 to 0.98, p=0.03). However, the relative risk of renal-replacement therapy alone was not significantly different between groups (HR 0.71, 95% CI 0.49 to 1.03, p=0.07). Secondary endpoints, including rates of bleeding and stroke, troponin T and creatine kinase levels, and time to hemodynamic stabilization, did not significantly differ between the two groups. Investigators concluded that the risk of death or severe renal failure was lower among those who underwent PCI of the culprit vessel alone, as compared to immediate PCI of multiple vessels.
Antiplatelet Therapy with Aspirin, Clopidogrel, and Dipyridamole versus Clopidogrel Alone or Aspirin and Dipyridamole in Patients with Acute Cerebral Ischemia (TARDIS): a Randomized, Open-Label, Phase 3 Superiority Trial
Dual antiplatelet therapy with aspirin and clopidogrel has been shown to be superior in preventing recurrent events in patients with cerebral ischemia, as compared to aspirin alone. Whether triple antiplatelet therapy with aspirin, clopidogrel, and dipyridamole is more effective compared to treatment using the current antiplatelet therapy guidelines, which recommend either clopidogrel alone or aspirin and dipyridamole together, is unclear. This randomized controlled trial enrolled 3,096 patients and assigned them to receive either triple therapy (aspirin 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice daily) or guideline-based therapy (either clopidogrel alone or combined aspirin and dipyridamole). Patients were followed-up for the combined incidence and severity of recurrent stroke or transient ischemia attack (TIA) within 90 days. Researchers found that there were significantly more bleeding events, as well as more severe bleeding, in the triple antiplatelet therapy group (OR 2.54, 95% CI 2.05 to 3.16, p<0.0001), without a significant difference in the primary end point between the two groups (OR 0.90, 95% CI 0.67 to 1.20, p=0.47). As such, the trial was stopped early. Investigators therefore concluded that triple antiplatelet therapy should not be used in patients with recent cerebral ischemia, as it does not improve the rate or severity of recurrent TIA or stroke but does increase the risk of severe bleeding events compared to current guideline-based therapy.
Hematopoietic-cell transplantation is frequently complicated by cytomegalovirus (CMV) infection. Investigators aimed to determine whether letermovir, an anti-viral that inhibits the CMV-terminase complex, could be used prophylactically to prevent this infection. CMV-seropositive transplant patients (n=565) were randomly assigned to receive either letermovir or placebo for 14 weeks post-transplant. Patients were followed for clinically significant CMV infection up to 24 weeks post-transplant. Researchers found that a significantly smaller proportion of patients treated with letermovir had clinically significant CMV infection with 37.5% of patients reaching the end point, as compared to 60.6% in the placebo group (p<0.001). Rates of adverse effects, such as vomiting, edema, myelotoxic and nephrotoxic events, and atrial fibrillation or flutter, were similar between the two groups. Investigators concluded that letermovir prophylaxis significantly lowers the risk of CMV infection in hematopoietic-cell transplant patients.
Many different strategies are used to try to prevent pre-term birth, as prematurity is a major cause of morbidity and mortality in neonates. One such strategy is a cervical pessary, a silicone device that keeps the cervix closed and redistributes the pregnancy weight. This randomized controlled trial enrolled 300 women with singleton pregnancies and ultrasound-confirmed short cervical length (<25 mm between 18 and 24 weeks) without a history of premature delivery. Women were randomly assigned to receive a cervical pessary or no pessary and were followed up for spontaneous preterm birth at less than 34 weeks. Researchers found that participants in the pessary group were less likely to deliver preterm compared to patients in the control group (RR 0.48, 95% CI 0.24 to 0.95, p=0.04). Vaginal discharge was significantly increased in the group assigned to receive the pessary device, however, other maternal adverse effects were not significantly different between the two groups. Researchers therefore concluded that the use of a cervical pessary in singleton pregnancies with short cervical length and no prior history of preterm delivery significantly lowers the risk of preterm birth at less than 34 weeks.
©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.